|
|
|
| First Name: | Sergey | | Last Name: | Bachurin | | Title: | Prof | | Advanced Degrees: | Dr. Sci | | Affiliation: | Inst. Physiol. Active Comp | | Department: | Laboratory of Neurochemistry | | Street Address 1: | IPAC RAS | | City: | Chernogolovka | | State/Province: | Moscow region | | Zip/Postal Code: | 142432 | Country/Territory: | Russia | | Phone: | 7-496-524-0113 | | Fax: | 7-496-524-0113 | | Email Address: |  |
Disclosure:
(view policy)
|
|
Aging Process, Alzheimer Disease
|
A-beta PP/A-beta, Chemistry/Pharmacology, Animal Models, Oxidative Stress, Drug screening, Neurotransmission
|
Sergey Olegovich Bachurin graduated from Moscow State University (MSU) in 1975. During the period of
1975-1980, he was a graduate student and employee of the Chemical Enzymology chair, MSU. In 1980, Bachurin defended a Ph.D. dissertation on ''Chemical Kinetics and Catalysism'', and doctor of science degree in "biochemistry" in 1993. From 1981 until the present time, he has been working at the Institute of Physiologically Active Compounds Russian Academy of Sciences
(IPAC RAS). Since 1986, he has been the Head of Laboratory of Neurochemistry. Since 2006 he is the Director of this institute.S. Bachurin has been an invited scholar at the
University of California, San Francisco, USA (1992) and at Tufts University School of Medicine, Boston, USA
(1995). He is a member of Scientific Councils of IPAC RAS and some other institutes, member of RAS Scientific Council on Biomolecular and Medicinal Chemistry, and Vice-Chairman of the Russian Society for Medicinal Chemistry.
During the last 5 years, S. Bachurin has been the Principal Investigator of 12 international and five Russian grants. He is also the author of more than 100 publications and about 20 patents.
He is a key inventor of novel promising medicine for Alzheimer's disease treatment - agent dimebon.
|
1. Rachelle S. Doody, Svetlana I. Gavrilova, Mary Sano, Ronald G. Thomas, Paul S. Aisen, Sergey O. Bachurin, Lynn Seely, David Hung. Dimebon improves cognition, behaviour, activities of daily living and global function in a randomised, double-blind, placebo-controlled 6-month study of patients with mild-to-moderate Alzheimer’s disease. Lancet, 2008, v.372: 207-215.
2. Patchev VK, Bachurin SO, Albers M, Fritzemeier KH, Papadopoulos V. Neurotrophic estrogens: essential profile and endpoints for drug discovery. Drug Discov Today, 2008, v.13, p:734-747
3. Bachurin S.O., Shevtsova E.P., Kireeva E.G., Oxenkrug G.F., Sablin S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. // Ann.N.Y Acad. Sci., 2003, v. 993: 334-344.
4. Grigoriev V.V., Drany О.А., Bachurin S.O. Comparative study of mechanism of action of agents Dimebon and Memantine on АМРА- and NMDA-subtypes of glutamate receptors. Bull Exp Biol Med., 2003, v.136, №11: 535-538.
5. Bachurin S.O. Medicinal chemistry approaches for treatment and prevention of Alzheimer's disease. Medicinal Research Reviews, 2003, v.23(1):48-88.
6. Tikhonova IG, Baskin II, Palyulin VA, Zefirov NS, Bachurin SO. Structural Basis for Understanding Structure-Activity Relationships for the Glutamate Binding Site of the NMDA Receptor. J Med Chem. 2002 Aug 29;45(18):3836-3843.
7. Shevtzova E.F., Kireeva E.G., Bachurin S.O. The effect of fragment of b-amyloid peptide 25-35 on nonselective permeability of mitochondria. Bull Exp Biol Med. 2001 Dec;132(12):652-656.
8. Oxenkrug G., Requintina P., Bachurin S. Antioxidant and Anti-Aging Activity of N-Acetylserotonin and Melatonin in the in vivo models. // Ann.N.Y Acad. Sci. 2001, v.939, 190-199.
9. Bachurin S., Tkachenko S., Baskin I., Lermontova N., Mukhina T., Petrova L., Ustinov A., Proshin A., Grigoriev V., Lukoyanov N., Palyulin V., Zefirov N. Neuroprotective and cognition enhancing properties of MK-801 flexible analogs. Structure-activity relationships. // Ann.N.Y Acad. Sci., 2001, v.939, 219-236
10. Bachurin, S., Bukatina, E., Lermontova, N., Tkachenko, S., Afanasiev, A., Grigoriev, V., Grigorieva, I., Ivanov, Yu., Sablin, S., Zefirov, N. Antihistamine agent Dimebon as novel neuroprotector and cognition enhancer. // Ann.N.Y Acad. Sci., 2001, v.939, 425-435.
|
Interrelation between beta-amyloidosis and neuronal cell death |
Gallardo G, Schluter OM, Sudhof TC. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci. 2008 Mar;11(3):301-8.
Heng Du, CyclophilinD deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’sdisease. Nat.Med. 2008, 14, 10:1097
Yu Sun et al., Mechanism of glutamate receptor desensitization
Nature, 417, 2002.
Stensbol TB, Madsen U, Krogsgaard-Larsen P. The AMPA receptor binding site: focus on agonists and competitive antagonists. Curr Pharm Des. 2002;8(10):857-72
Jacob S, Poeggeler B, Weishaupt JH, Siren AL, Hardeland R, Bahr M, Ehrenreich H. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients.
|
beta-amyloid nature of AD |
|
|
Home
